Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

Abstract

Background:

Residual platelet reactivity is a predictor of poor prognosis in patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention. Thrombin is a major platelet activator and upon initiation of the coagulation cascade, it is subsequently produced downstream of factor IXa, which itself is known to be increased in ACS. Pegnivacogin is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen. We hypothesized that pegnivacogin could reduce platelet reactivity.

Methods:

Whole blood samples from healthy volunteers were incubated in vitro in the presence and absence of pegnivacogin and platelet reactivity was analysed. In addition, platelet aggregometry was performed in blood samples from ACS patients in the RADAR trial featuring the intravenous administration of pegnivacogin as well as reversal by anivamersen.

Results:

In vitro, pegnivacogin significantly reduced adenosine diphosphate-induced CD62P-expression (100% vs. 89.79±4.04%, p=0.027, n=9) and PAC-1 binding (100% vs. 83.02±4.08%, p=0.010, n=11). Platelet aggregation was reduced (97.71±5.30% vs. 66.53±9.92%, p=0.013, n=10) as evaluated by light transmission aggregometry. In the presence of the RNA-aptamer reversal agent anivamersen, neither CD62P-expression nor platelet aggregation was attenuated. In patients with ACS treated with aspirin and clopidogrel, residual platelet aggregation was significantly reduced 20 min after intravenous bolus of 1 mg/kg pegnivacogin (100% versus 43.21±8.23%, p=0.020).

Conclusion:

Inhibition of factor IXa by pegnivacogin decreases platelet activation and aggregation in vitro. This effect was negated by anivamersen. In ACS patients, platelet aggregation was significantly reduced after intravenous pegnivacogin. An aptamer-based anticoagulant inhibiting factor IXa therefore might be a promising antithrombotic strategy in ACS patients.

Keywords

Anticoagulation acute coronary syndromes factor IX factor IXa residual platelet reactivity anticoagulant reversal

Get full access to this article

View all access options for this article.

References

Libby

. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368: 2004–2013.

Windecker

Kolh

Alfonso

, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: web addenda. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541–2619.

Amsterdam

Wenger

Brindis

, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: e344–e426.

Ahrens

Bode

. New parenteral anticoagulants: Focus on factor Xa and thrombin inhibitors. Curr Drug Discov Technol 2012; 9: 129–136.

Ahrens

Bode

Zirlik

. Anticoagulation during and after acute coronary syndrome. Hamostaseologie 2014; 34: 72–77.

Doktorova

Motovska

. Clinical review: Bleeding – a notable complication of treatment in patients with acute coronary syndromes: Incidence, predictors, classification, impact on prognosis, and management. Crit Care 2013; 17: 239.

Sofi

Marcucci

Gori

, et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events–a meta-analysis. Int J Cardiol 2008; 128: 166–171.

Parodi

Marcucci

Valenti

, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011; 306: 1215–1223.

Tantry

Bonello

Aradi

, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261–2273.

10.

Brass

. Thrombin and platelet activation. Chest 2003; 124: 18s–25s.

11.

Coughlin

. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258–264.

12.

Ahrens

Lip

Peter

. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49–60.

13.

Dyke

Steinhubl

Kleiman

, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114: 2490–2497.

14.

Tanaka

Szlam

Rusconi

, et al. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost 2009; 101: 827–833.

15.

Catuogno

Esposito

de Franciscis

. Developing aptamers by cell-based SELEX. Methods Mol Biol 2016; 1380: 33–46.

16.

Rusconi

Roberts

Pitoc

, et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 2004; 22: 1423–1428.

17.

Shattil

Cunningham

Hoxie

. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307–315.

18.

Ahrens

Habersberger

Baumlin

, et al. Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. Atherosclerosis 2011; 218: 431–434.

19.

Povsic

Cohen

Mehran

, et al. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial. Am Heart J 2011; 161: 261–268. e1–2.

20.

Ault

Cannon

Mitchell

, et al. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 33: 634–639.

21.

Minnema

Peters

de Winter

, et al. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2489–2493.

22.

Povsic

Vavalle

Alexander

, et al. Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Results from the phase II RADAR-PCI study. EuroIntervention 2014; 10: 431–438.

23.

Lincoff

Mehran

Povsic

, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): A randomised clinical trial. Lancet 2016; 387: 349–356.

24.

Bernlochner

Mayer

Orban

, et al. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. Platelets 2016: 1–9.

25.

Zeymer

Widimsky

Danchin

, et al. P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: Use, patient selection, and outcomes from contemporary European registries. Eur Heart J Cardiovasc Pharmacother 2016: pvw005.

26.

Moser

Olivier

Bode

. Triple antithrombotic therapy in cardiac patients: More questions than answers. Eur Heart J 2014; 35: 216–223.

27.

Gui

Reheman

Funkhouser

, et al. In vivo response to vascular injury in the absence of factor IX: Examination in factor IX knockout mice. Thromb Res 2007; 121: 225–234.

28.

Swieringa

Kuijpers

Lamers

, et al. Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow. Haematologica 2015; 100: 748–756.

29.

Podoplelova

Sveshnikova

Kotova

, et al. Blood coagulation factors bound to procoagulant platelets are concentrated in their cap structures to promote clotting. Blood 2016; 128: 1745–1755.